Professional Education

  • Doctor of Philosophy, University of Texas at Austin, Biomedical Engineering (2020)
  • Master of Science in Engineering, University of Texas at Austin, Biomedical Engineering (2018)
  • Master of Engineering, Tokyo Institute of Technology, Electrochemistry (2015)
  • Bachelor of Science, Tokyo University of Science, Applied Chemistry (2013)

Stanford Advisors

Contact

  • Academic
    eritake@stanford.edu
    University - Scholar Department: Surgery Position: Postdoctoral Scholar

Additional Info

  • Mail Code: 5148

All Publications

  • Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation NATURE COMMUNICATIONS Takematsu, E., Massidda, M., Auster, J., Chen, P., Im, B., Srinath, S., Canga, S., Singh, A., Majid, M., Sherman, M., Dunn, A., Graham, A., Martin, P., Baker, A. B. 2022; 13 (1): 2497

    Abstract

    Stem cell factor (SCF) is a cytokine that regulates hematopoiesis and other biological processes. While clinical treatments using SCF would be highly beneficial, these have been limited by toxicity related to mast cell activation. Transmembrane SCF (tmSCF) has differential activity from soluble SCF and has not been explored as a therapeutic agent. We created novel therapeutics using tmSCF embedded in proteoliposomes or lipid nanodiscs. Mouse models of anaphylaxis and ischemia revealed the tmSCF-based therapies did not activate mast cells and improved the revascularization in the ischemic hind limb. Proteoliposomal tmSCF preferentially acted on endothelial cells to induce angiogenesis while tmSCF nanodiscs had greater activity in inducing stem cell mobilization and recruitment to the site of injury. The type of lipid nanocarrier used altered the relative cellular uptake pathways and signaling in a cell type dependent manner. Overall, we found that tmSCF-based therapies can provide therapeutic benefits without off target effects.

    View details for DOI 10.1038/s41467-022-30103-2

    View details for Web of Science ID 000791826000010

    View details for PubMedID 35523773

    View details for PubMedCentralID PMC9076913

  • Genome wide analysis of gene expression changes in skin from patients with type 2 diabetes PLOS ONE Takematsu, E., Spencer, A., Auster, J., Chen, P., Graham, A., Martin, P., Baker, A. B. 2020; 15 (2): e0225267

    Abstract

    Non-healing chronic ulcers are a serious complication of diabetes and are a major healthcare problem. While a host of treatments have been explored to heal or prevent these ulcers from forming, these treatments have not been found to be consistently effective in clinical trials. An understanding of the changes in gene expression in the skin of diabetic patients may provide insight into the processes and mechanisms that precede the formation of non-healing ulcers. In this study, we investigated genome wide changes in gene expression in skin between patients with type 2 diabetes and non-diabetic patients using next generation sequencing. We compared the gene expression in skin samples taken from 27 patients (13 with type 2 diabetes and 14 non-diabetic). This information may be useful in identifying the causal factors and potential therapeutic targets for the prevention and treatment of diabetic related diseases.

    View details for DOI 10.1371/journal.pone.0225267

    View details for Web of Science ID 000535227900006

    View details for PubMedID 32084158

    View details for PubMedCentralID PMC7034863

  • In vivo osteoconductivity of surface modified Ti-29Nb-13Ta-4.6Zr alloy with low dissolution of toxic trace elements. PloS one Takematsu, E., Noguchi, K., Kuroda, K., Ikoma, T., Niinomi, M., Matsushita, N. 2018; 13 (1): e0189967

    Abstract

    Simulated Body Fluid (SBF) has served as a useful standard to check the bioactivity of implant materials for years. However, it is not perfectly able to imitate human serum; sometimes disparities between the SBF test and animal test were confirmed. Therefore, to ensure the reliability of the results of the SBF test obtained from our previous study, an animal study was performed to check osteoconductivity of surface modified implant materials. Three types of solution processes, hydrothermal (H), electrochemical (E), and hydrothermal-electrochemical (HE), were performed on the Ti-29Nb-13Ta-4.6Zr alloy (TNTZ) to improve its bioactivity, and their bioactivities were measured in vivo using bone-implant contacts (BICs). BICs of the HE- and H-treated samples were significantly higher than that of the control. Metal ion diffusion towards the bone was also evaluated to examine the adverse effect of metal ions. No metal ion diffusion was observed, indicating the safety of our solution processed implant materials.

    View details for DOI 10.1371/journal.pone.0189967

    View details for PubMedID 29342150

    View details for PubMedCentralID PMC5771579

  • Adhesive strength of bioactive oxide layers fabricated on TNTZ alloy by three different alkali-solution treatments. Journal of the mechanical behavior of biomedical materials Takematsu, E., Cho, K., Hieda, J., Nakai, M., Katsumata, K., Okada, K., Niinomi, M., Matsushita, N. 2016; 61: 174-181

    Abstract

    Bioactive oxide layers were fabricated on Ti-29Nb-13Ta-4.6Zr alloy (TNTZ) by three different alkali solution treatments: hydrothermal (H), electrochemical (E), and hydrothermal-electrochemical (HE). The adhesive strength of the oxide layer to the TNTZ substrate was measured to determine whether this process achieves sufficient adhesive strength for implant materials. Samples subjected to the HE process, in which a current of 15mA/cm(2) was applied at 90°C for 1h (HE90-1h), exhibited a comparatively higher adhesive strength of approximately 18MPa while still maintaining a sufficiently high bioactivity. Based on these results, an oxide layer fabricated on TNTZ by HE90-1h is considered appropriate for practical biomaterial application, though thicker oxide layers with many cracks can lead to a reduced adhesive strength.

    View details for DOI 10.1016/j.jmbbm.2015.12.046

    View details for PubMedID 26866453

  • Bioactive surface modification of Ti-29Nb-13Ta-4.6Zr alloy through alkali solution treatments. Materials science & engineering. C, Materials for biological applications Takematsu, E., Katsumata, K., Okada, K., Niinomi, M., Matsushita, N. 2016; 62: 662-7

    Abstract

    Bioactive surface modification of Ti-29Nb-13Ta-4.6Zr alloy (TNTZ) was performed through three different alkali solution treatments, including the electrochemical (E), hydrothermal (H), and hydrothermal-electrochemical (HE) processes; all of the processes lead to the formation of sodium-contained amorphous titanium oxide layers on TNTZ samples. The TNTZ samples subjected to the E, H, and HE processes exhibit a flat surface, smooth and fine mesh-like structure surface, and rough mesh-like structure surface, respectively. In the bioactive test, namely, simulated body fluid test, apatite inductivity increases as the surface morphology becomes rough. The order of inductivity for the three processes was HE>H>E. The surface chemical composition also affects the apatite induction ability. The surface with fewer niobium species exhibits better apatite inductivity.

    View details for DOI 10.1016/j.msec.2016.01.041

    View details for PubMedID 26952470